Focused on the development of therapies for hematological malignancies and with a very limited SBIR presence, Biotheryx was founded by the drug development team behind a class of anti-cancer drugs globally - the IMiD franchise of compounds launched at Celgene. IMiDs are the only class of clinically-validated protein degrading compounds currently commercially available. Identification of the E3 ligase Cereblon (CRBN) as a key target of IMiD compounds confirmed targeted protein degradation as a viable drug development strategy, which could provide significant therapeutic benefits and enormous commercial success. Utilizing this extensive knowledge, experience, and expertise to deliver efficacious therapies for unmet medical needs in cancers and inflammatory diseases utilizing small molecules that can be delivered orally or via injection/infusion and having an extensive portfolio of issued and pending patents, BioTheryX decsribes iself as one of the few companies with a large portfolio of IP-protected, CRBN-binding small molecules, and the drug development team is building a set of high-value assets in protein modulation, including protein degradation as well as multi-kinase inhibition.
